 |
Press Release
|
Boehringer Ingelheim Cares Foundation, Inc. Donates Combivent® and FLOMAX® to Florida Hurricane Relief
- Products recently shipped to three State relief centers -
RIDGEFIELD, CT - Sept. 14, 2004 - The Boehringer Ingelheim Cares Foundation, Inc. has donated pharmaceutical medicines to the state of Florida's Hurricane Relief Efforts as a means of helping the many thousands of citizens whose lives have been impacted by recent storms there.
At the request of the Florida Department of Health, the Boehringer Ingelheim Cares Foundation, Inc. has shipped a total of 1,300 units of Combivent® (ipratropium bromide and albuterol sulfate) and 240 bottles (100 capsules each) of FLOMAX® (tamsulosin hydrochloride) to emergency clinics set up in at least three relief centers across Florida.
"We are deeply concerned about the health and wellbeing of patients throughout Florida in their time of need," said Ralph Craft, President of the Boehringer Ingelheim Cares Foundation. "By making this donation of Combivent and Flomax, we hope to provide some measure of relief to those who may not otherwise have a way of obtaining these products because of the damage caused by current hurricanes. We are pleased to be a part of the effort to help."
About the Boehringer Ingelheim Cares Foundation
The Boehringer Ingelheim Cares Foundation, Inc. is an independent, charitable organization established in 2001 by the Boehringer Ingelheim Corporation (Ridgefield, Connecticut). The Foundation's mission is to improve lives through innovative philanthropic contributions and donations of healthcare products and resources.
About Boehringer Ingelheim Corporation
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 152 affiliates in 45 countries and more than 34,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2003, Boehringer Ingelheim posted net sales of US $8.37 billion (7.4 billion euro) while spending more than one fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com
Boehringer Ingelheim Cares Foundation, Inc.
Ralph Craft, President
900 Ridgebury Rd./P.O. Box 368
Ridgefield, CT 06877-0368